News & events

We are taking our ambition to be as green as possible to a new level. Now by offering our employees the possibility to commute in a green way.

As a natural consequence of our Circular for Zero environmental strategy we have established 10 parking spaces with charging stations for electric vehicles. This makes it even more attractive to commute in a green way.

Our employee Lene Hoffmeyer Nielsen is very pleased with the new parking spaces:

“The new charging stations at our site is the main reason why we have ordered a Plug-in hybrid car. The possibility to get the car charged during the day and not having to have a charging station at home makes a huge difference. This way I´m also contributing to reducing the CO2 level, which gives a nice “green” feeling.

At Novo Nordisk Pharmatech we have been CO2 neutral since 2018. Our gas consumption comes from Biogas and we are only supplied with renewable energy, produced by windmills. This means that we have zero CO2 emissions from energy consumption. Even our grass is mowed by a robotic automower which runs on our power from windmills.

If you wish to read more about our strategy, you can do this in our Annual report.

Friday 31.07.2020

Supply chain safety, quality and reliability are key to all our Quats and Insulin Human customers. Here is how we can help you secure your supply chain, from sourcing raw materials to delivering your products as promised – even in a global crisis.

A secure supply from a pharma organisation

As part of a large pharma group, we are uniquely positioned to help both our Quats and Insulin Human customers secure their supply chains. We source our Recombinant Insulin directly from our parent company Novo Nordisk, the world’s largest producer, for a secure supply of high quality insulin. Being part of a large organisation also puts us in a strong position for sourcing raw materials from our key Quats suppliers.

We are a specialist and dedicated manufacturer of Quats in an unequalled, full cGMP grade. This reduces your supply chain risk for products such as Benzalkonium Chloride, compared with non-pharma manufacturers of multiple products or APIs. You can be sure of where our products come from and that they meet all the necessary specifications.

Quality and consistency you can rely on  

Insulin production is complex: any variation in the manufacturing process, both upstream and downstream, can have serious effects on the insulin’s consistency. For the same performance every time, consistency is a must. With very few manufacturing batches a year, the large scale of our manufacturing and our highly standardised processes ensure product consistency. With a long history of compliance, our Insulin Human is manufactured in cGMP facilities, following our ISO 9001 quality system. It is analysed according to the current European Pharmacopoeia (Ph. Eur.) and the United States Pharmacopoeia (USP).

All our Quats products are manufactured according to cGMP and ICH Q7 guidelines. This ensures the right quality products, with a high degree of consistency. Our multi-compendial range of products follows the European Pharmacopoeia (Ph. Eur.) and the United States Pharmacopoeia (USP). Some Quats products also follow the Japanese Pharmacopoeia (JP) or the British Pharmacopoeia (BP). You therefore have complete assurance that products will meet regulatory guidelines. All our Quats activities are gathered in one site in Denmark, making supply chain audits even easier.

We provide a simple, ‘one-stop’ solution to regulatory compliance for both our Quats and Insulin Human customers, with up-front access to a full package of certificates from authorities, qualification dossiers, stability and analysis documents, and more. We also have a dedicated customer support department to provide a swift response to any questions you might have.

Delivering as promised around the world

Our Quats products are sold globally in more than 70 countries across Europe, Asia, North America, South America and Africa. We supply some of our customers directly, but we are also supported by a network of global distributors across North America, Europe, Asia, Australasia and India. This gives customers access to a local supplier and point of contact for their products. In-stock pharmaceutical products can be shipped within a week, and our entire range of products is offered in a variety of packing solutions, meeting demands for small- and large-size packaging. Our Quats products are also distributed in line with GDP and Known Consignor.

Insulin Human is filled in our own classified room facilities using tamper-proof packaging. These are placed in approved thermo-containers together with dry ice to ensure that the product is kept below the recommended maximum temperature during shipment. Customers might be surprised to learn that we do not have a requalification process; if the product is not delivered, or re-icing is not performed, the product is simply scrapped. Local distribution centres – in Indiana, USA, and near Copenhagen, Denmark – also provide short lead-times and precision delivery worldwide.

Ensuring business continuity during crisis

Covid-19 has put supply chains to the test, with gaps rapidly emerging. However, it has been more or less business as usual for us. As a pharma company, our business was deemed essential by governments around the world. By working closely with our customers, we are delivering our products as promised and without disrupting planned manufacturing processes.

We are continuing to monitor the situation closely, and of course we have business continuity plans in place to ensure ongoing, safe operations, as well as product stockpiles to cover customer requirements.

For more information, please contact:

Insulin: Timur Özbay at [email protected]

Quats: Phil Stafford at [email protected]

You can download the article here.

Wednesday 22.07.2020

Long seniority and high professionalism are both important cornerstones in our business. Almost half of our colleagues have a seniority above 10 years in the Novo Nordisk Group. And we actually have 9 employees (out of 193 in total) with a seniority higher than 30 years.

Meet Anne Ammitzbøll. Anne has worked in the Novo Nordisk Group for 35 impressive years. She started as a Laboratory Technician and has been in her current position in our QC (Quality Control) in Køge since 1998.

“My position and department have changed a lot during the years and thanks to my versatile assignments, 22 years in QC has not felt like a long time. At Novo Nordisl Pharmatech we all know each other and if you need help or information, you can easily approach your colleagues directly regardless of department or level in the organisation. Although over the years we have increased the number of employees from 60 to close to 200.”

Anne is currently studying an Academic Management. We are excited to see what the future brings for her.

Wednesday 15.07.2020

Europe´s leading Bioprocessing event is taking place July 13-17 – and Novo Nordisk Pharmatech is an active part of the event. You will here get much more information about our Insulin Human AF and how it can help you in your upstream processes.

The conference and exhibition was original planned for April and then moved to new dates due to COVID-19. Now it will be held as a 100% virtual event.

Do you want to visit our virtual booth and have a chat with Gernot Stadlmann, Timur Özbay or Lene Hoffmeyer Nielsen? You can register for the FREE virtual exhibition visitor pass here.

The virtual exhibition is featuring 50+ bioprocessing technology displays and the virtual poster hall featuring 20+ peer-submitted scientific posters.

If you are not able to attend and have questions for us, you can always find our contact information here.

Friday 03.07.2020

Our customers depend on us to deliver their needed products – even when we are facing a pandemic as COVID-19. While our customers depend on us, we depend on our employees.  Without them and their ability to work under changed conditions, we could have faced great problems the last couple of months.

Meet our Supply Chain team. As the COVID-19 pandemic was advancing, our Supply Chain team faced a big challenge: The increased amount of potential shortages that could stop production to the great disadvantage of our many customers. At the same time, they had to adapt to working remotely, handling the work/life balance and ensuring to stay safe and healthy.

Quick reaction in evaluating risks, around the clock communication with suppliers, acceptance to constantly navigate and plan across many uncertain scenarios – and finally the desire to give it all for the company and our clients. This was their key to succeed. Of course, the support from the other teams at Novo Nordisk Pharmatech and our suppliers was also essential. The high degree of flexibility and adaptability across all stakeholders ensured that the inbound supply and production planning succeeded.

Thursday 02.07.2020

Our innovation: A wide range of capabilities are available at Novo Nordisk Pharmatech A/S within the various departments; Sales and Marketing, R&D, Manufacturing, Quality, Business Support and HR & Communication. They are all critical for us to run the business and innovate. The following “Core Capabilities” are fundamental to the future growth of our company:

  • Designing and developing silica gels: We have long history of continuously reducing the cost for Novo Nordisk of producing insulin by providing robust silica gel and developing processes for increasing their life time.
  • Advanced microanalysis: At our Microanalysis Centre our team supports Novo Nordisk with state-of-the-art microscopy and spectroscopic support. This capability is also critical for the development of new chromatographic resins.
  • Organic chemical synthesis manufacturing: We have from the outset produced Quats by organic synthesis manufacturing and has led to our solid experience.
  • cGMP embedded throughout the organisation: Biopharmaceutical companies are required to operate in accordance to cGMP to ensure patient safety. For us to be a preferred supplier to the biopharmaceutical industry cGMP therefore is a key capability.

Contact us for further information here.

Thursday 11.06.2020

You can increase viable CHO cell density by supplementing with recombinant Insulin Human AF. CHO cells are one of the most widely used platforms to produce biopharmaceuticals.

Increased demand for safety and reliability has moved the standard for CHO cell culture media from Serum to Serum free, and further on to chemically defined media.

UAB (Universitat Autònoma de Barcelona), in collaboration with Novo Nordisk Pharmatech A/S, has shown that the addition of animal origin free insulin to three leading commercially available, off-the-shelf chemically defined media, resulted in significant increases in viable cell density under batch-mode culture. This led to improve cell growth up to 53 % and 66% of targeted protein production.

In addition to this benefit, insulin has been proven to aid in the expression of proteins that are difficult to express.

You can read or download the result of the study here.

Thursday 04.06.2020

We will develop our employees. This is one of our goals at Novo Nordisk Pharmatech. Therefore, from the first day we encourage our employees to think about their continuing education. Not necessarily for the position they have now. But to make sure that they are ready for any future positions. Internally or externally.

An example of this is our Global Marketing Manager Marie-Louise Lyster Andersen. Marie-Louise started working at Novo Nordisk Pharmatech on January 1th 2020 and has already started her first training with an external partner:

“It is very satisfying to work at a company that is not reluctant in terms of education, even though my seniority is not that high. But at NNPR, I have been encouraged to expand my skills as part of my Individual Development Plan. Besides the benefits of increased skills, it naturally affects my job satisfaction in a positive way.”

Do you also want to be part of Novo Nordisk Pharmatech? You can always find our vacant positions here.

Thursday 28.05.2020

How do we ensure the quality of materials and products? What are the benefits of using cGMP Quats as excipients? And how does Novo Nordisk Pharmatech ensure to stay on top of the pace of technology change?

Did you have the chance to read the article in Pharma Focus Asia, where our Corporate Vice President Rasmus Hother le Fevre talks about the industry challenges on product quality and how to ensure a good quality?

If not, you can read the article here.

Friday 15.05.2020

Novo Nordisk Pharmatech has been a CO2 neutral company since 2018. This environmental improvement is due to an agreement from 2015 on energy distribution, which ensures we are only supplied with renewable energy, produced by windmills. In 2018, another agreement was made regarding our gas consumption, which now comes from Biogas. This means that we have zero CO2 emissions from energy consumption. In 2019 we also committed to the Novo Nordisk Circular for Zero environmental strategy. This means we will strive to have zero environmental impact by 2030.

We are committed to the following targets, according to our environmental policy:

  • We reduce our waste volumes, noise impacts and emissions into the air
  • We reduce our CO2 emissions
  • We run our business safely by conducting environment and risk assessments for all activities
  • We will continue to systematically minimize the environmental impact when we develop new products and processes
  • We will continue to encourage our customers to co-operate in the development of environmentally-sound products and services
  • We regularly report on environmental efforts and performance
  • We maintain an open and trustworthy dialogue with our stakeholders
  • We encourage staff environmental awareness to ensure an environmentally-sound culture

Thursday 07.05.2020

Did you know that we at Novo Nordisk Pharmatech have 70 years of extensive experience supplying Quats (quaternary ammonium compounds) for the biopharmaceutical and pharmaceutical industries? Do you also know the story behind our company name?

In 1949 Ferrosan Fine Chemicals factory was established. In 1986 we were acquired by Novo Nordisk. In 1992 the name was changed to FeF Chemicals A/S – and on September 1th 2015 we changed to the name, we have today: Novo Nordisk Pharmatech A/S. At the same time our current Corporate Visual Identity was created including the well-known Novo Nordisk bull.

All the way we have maintained our position as the best supplier of high-quality ingredients for the biopharmaceutical and pharmaceutical industries.

Are you interested in knowing more about our way of doing business – and about our accomplishments and results? You can learn more in our Annual Report for 2019 here

Thursday 30.04.2020

Every year, we at Novo Nordisk Pharmatech publish a single, integrated report on our performance.

Read the Annual Report 2019 here and learn more about our accomplishments and results, our way of doing business and our financial statements.

Monday 27.04.2020

Imagine a blockbuster drug. Now keep it on track.

Every new idea needs great execution. We can help, with a reliable supply of the highest quality ingredients for the biopharmaceutical and pharmaceutical industries:

Recombinant Insulin for cell growth media and pharmaceutical grade Quaternary Ammonium Compounds. Both manufactured to cGMP standards.

Our proven record of precision delivery and product quality allows you to keep development on track, production flowing, and products supplied to hospitals and patients. Giving you the security, you need to focus on the next big breakthrough.

Our experts are always ready to support you. You can find their contact information here.

Thursday 23.04.2020

Our full cGMP processes make Novo Nordisk Pharmatech the leading supplier of pharmaceutical grade Quats (quaternary ammonium compounds) for a wide range of applications.

Benzalkonium Chloride, Cetrimide and Cetrimonium Bromide (CTAB) in cGMP grade are particularly suited as active ingredients and excipients in pharmaceuticals, or process aids for biopharmaceuticals.

Proven under ICH Q1 conditions, our Quats are very stable. They are powerful antimicrobial surfactants, soluble both in aqueous and oily phases and basically active at all pH ranges. They can be used for a large number of applications requiring high purity and quality, such as ophthalmics, nasal sprays, wound care/topical/oral/dental and veterinary products, medical devices, vaccine and gene therapy processes.

We offer an extensive range of documentation to help you meet registration and regulatory requirements. This includes multicompendial analysis, and access to regulatory documentation, such as Drug Master Files and our Ph.Eur. Certificates (CEP) for Benzalkonium Chloride and Cetrimide.

Learn more about possible applications here.

Thursday 16.04.2020

Almost four weeks has passed since the first announcement came that we had to rearrange our daily life to break the Corona infection chain. Plans were made in regard to prioritizing within the frame set by the authorities and it was quickly evident that we are change ready and flexible in solving that task. This way we can still ensure that our customers will receive the same high-quality products as always.

One thing is the professional part of working and finding new solutions to that. Another thing is the importance of the social element, which becomes very distinct in a situation like this. Many online meetings are being held in and across departments. Even social events are held online. The Novo Nordisk Pharmatech (NNPR) United spirit has shown itself from its best side.

Should you have any questions to the current situation at the time being, please do not hesitate to contact us here.

Wednesday 08.04.2020

To enhance cell growth and viability for your innovative biologics, you can work with the leading supplier of recombinant insulin, Novo Nordisk Pharmatech.

We source our recombinant insulin directly from our mother company Novo Nordisk, the world’ s largest insulin producer. Thanks to our solid supply chain, you can keep development on track, production flowing, and products supplied to hospitals and patients.

Whether you work with HEK, CHO, SF9 insect, CAR-T or stem cells, you will be provided with the right quality ingredients for your projects, supplemented with appropriate documentation – even tailoring our solutions to match your specific application needs.

Why grow your cells with our insulin? Many of the world´s leading pharmaceutical companies already do. Enhanced viability and yield in your production, combined with our manufacturing and quality control, precision delivery, risk mitigation strategy and continuous availability, are only a few reasons.

Do you want to know more about our Insulin Human AF?

Thursday 02.04.2020

Whether you are manufacturing bacterial or viral vaccines, you want to minimize risks in your process by only using the purest and safest ingredients and materials.

CTAB, called Cetrimonium Bromide or Cetyl Trimethyl Ammonium Bromide, is a powerful cationic surfactant for use in vaccine downstream purification steps.

It is recommended by the WHO for the precipitation step of polysaccharide-based bacterial vaccines. It is also used as a purification agent of viral antigens, whether the vaccine is egg-based, cell-based or recombinant.

Utilizing chttps://www.linkedin.com/company/68003/GMP manufactured, pharma grade ingredients and processing aids can help you secure your vaccine production and minimize your risks.

As a unique feature on the market, Novo Nordisk Pharmatech A/S´s high purity CTAB is manufactured in cGMP API grade.

Read more on CTAB in vaccines here.

Friday 27.03.2020

COVID-19: Looking for an effective antimicrobial agent? Benzalkonium Chloride (BKC) is recommended by several national agencies as an effective agent to control infection by Covid-19.

BKC, a Quaternary Ammonium Compound (or Quat), is an ideal antimicrobial agent with proven efficacy. It is broadly used in topical and wound care products such as hand sanitizers, antiseptic liquids, foams, gels and cleansing wipes. BKC acts on a wide range of microorganisms, including enveloped viruses such as influenza and Corona, gram+ and gram- bacteria such as MRSA, moulds and yeasts such as Candida albicans.

As opposed to bacteriostatic/fungistatic compounds which only prevent micro-organisms from dividing (growing), Quats are bactericidal/fungicidal: They will kill micro-organisms in a growth phase or not. Quats are effective at all pH levels, and their effectiveness increases when the pH increases. The higher the pH, the lower the concentration needed to obtain an antimicrobial effect.

No matter the formulation, products coming in contact with either healthy or damaged epithelial tissue, must be manufactured with great care, using the best quality and safest ingredients. All our Quats are manufactured cGMP, at the highest purity and grade.

You can read more here.

Friday 20.03.2020

The vaccine industry is challenged to produce large quantities of vaccines in a rapid and cost-effective way. Major changes to current bioprocesses are both difficult and very expensive to implement. Using HEK293, it has been demonstrated that addition of recombinant human insulin to commercially available chemically defined media can be used as a supplement to increase VCD and specific viral yield.

If you want to know more you can read the application study, which National Research Council Canada has created in collaboration with Novo Nordisk Pharmatech A/S here.

Friday 13.03.2020

Novo Nordisk Pharmatech A/S is continuously reviewing the likely impact upon its supply chain if product availability is affected by the consequences of the coronavirus. Presently, we conclude that the impact on current product portfolio is very limited. We will keep our customers informed of developments that might affect product supply and demand if the situation changes.

You can read the full statement here

Thursday 12.03.2020

In our ambition to build and maintain customer loyalty all around the world, Novo Nordisk Pharmatech A/S started using NPS (Net Promotor Score) in 2014. It was – and still is – a simple tool to clarify if our customers are as satisfied as we think they are and whether they would recommend us to others. We also receive great input in the comments on where we can improve our business.

Since 2014 we have significantly improved our NPS score*, and in 2019 we had an impressive average score of 76. NPS scores range from -100 to 100.

Do you also want to become one of our loyal customers and ambassadors? You can always find our contact information here.

* Subtracting the percentage of Detractors from the percentage of Promoters gives the Net Promoter Score. Promoters (score 9-10) are loyal enthusiasts. Passives (score 7-8) are satisfied but unenthusiastic customers. Detractors (score 0-6) are unhappy customers. NPS score can range from a low of -100 (if every customer is a Detractor) to a high of 100 (if every customer is a Promoter).

Monday 10.02.2020

At Novo Nordisk Pharmatech we always strive to develop and provide high quality products and services that place emphasis on the health and safety of our consumers and customers. As of January 1st, 2020 our new Director of Manufacturing is John Halfdan Boiesen. John will be heading up the NNPR manufacturing facility ensuring that we deliver high quality products in regulatory compliance.

Part of the Manufacturing responsibility is to ensure that NNPR has all necessary permissions to operate and operate with minimal environmental impact.

John Boiesen started his career at Novo Nordisk in 2005 as a Supply Chain Graduate and since 2007, John has held various leadership positions in Novo Nordisk A/S – Product Supply within supply chain, warehouse and business support. We are happy to welcome John and if you need to contact him, please find his contact information here.

Friday 31.01.2020

We are pleased to announce that Chantale Julien has re-joined Novo Nordisk Pharmatech on January 1st, 2020. Chantale will be acting as Global Product Manager for the FeF Quats and Insulin Human AF products.

Chantale has previously worked for Novo Nordisk Pharmatech for a period stretching over almost 13 years, where she has been acting as Product Manager, Regulatory Affairs Manager and Project Manager. She has been involved in establishing the Insulin Human AF distribution from Novo Nordisk Pharmatech and brings back a wide experience in the API and excipient sectors for our antimicrobial quaternary ammonium compounds.

We are happy to have an experienced employee back on the team. You are welcome to contact Chantale if you need technical advice, for new product-related projects, and general product information. You can find here contact information here.

Thursday 23.01.2020

The grand opening of Novo Nordisk Pharmatech A/S new branch office in Singapore on October 15th 2019 was celebrated together with customers, employees and other stakeholders.

At Novo Nordisk Pharmatech A/S we opened our first overseas representative office with a Grand Opening ceremony for our new branch in Singapore. The event marks a significant new expansion milestone in the 70-year history of Novo Nordisk Pharmatech. The new branch office at 152 Beach Road, #17-04 The Gateway East has been in operation since September, serving as a hub to expand Novo Nordisk Pharmatech’s business across Asia.

The region is a rapidly growing market for our varied portfolio of leading-edge Quaternary ammonium (QUATS) and other compounds, as well as recombinant human insulin AF.

Novo Nordisk Pharmatech Managing Director and Corporate Vice President Rasmus Hother Le Fevre attended the Grand Opening ceremony and reception for customers, employees and other stakeholders.

“We are thrilled to be expanding our footprint into Asia,: said Mr. Hother Le Fevre.

“This new office is in close proximity to some of the world’s leading biopharmaceutical companies with direct access to leading regional clusters of biopharma and biotech development that are the main focus of our own activities,” he explained.

“Our new Singapore presence enhances our ability to deliver the high quality QUATS and recombinant insulin for cell culture media to the pharma and biopharma industries,” he added.

“A local Singapore branch office was a logical step in our business growth strategy and presents a superb opportunity for Novo Nordisk Pharmatech to strengthen our presence in a region where we have been increasingly active for several years,” said Mr. Hother Le Fevre.

Friday 11.10.2019

Novo Nordisk Pharmatech A/S and DKSH, have partnered to provide high-quality cGMP quaternary ammonium compounds in eleven markets across Asia Pacific.

DKSH’s Business Unit Performance Materials, a leading ingredients and specialty chemicals distributor, will distribute Novo Nordisk Pharmatech’s pharmaceutical grade compounds (quats) to its large customer base in Australia, New Zealand, Japan, Indonesia, South Korea, Thailand, Malaysia, Philippines, China, Taiwan and Singapore.

Novo Nordisk Pharmatech manufactures its pharmaceutical quats in accordance with the cGMP Guide ICH Q7 for Active Pharmaceutical Ingredients (APIs), the highest available quality standard in the industry. The quats, Benzalkonium Chloride (BKC), Cetrimonium Bromide (CTAB), Cetrimide and Strong Cetrimide, act either as preservatives or active ingredients in a diverse range of applications, including ophthalmic, nasal, oral, dental or topical treatments and medical devices, such as wound care.

DKSH was chosen for its proven experience in providing Market Expansion Services along the entire value chain and for its solid logistics infrastructure. As a regional expert with more than 150 years of experience in Asia, DKSH offers an omni-channel approach that presents a one-stop regional solution for its clients. DKSH provides tailored valued-added services and a deep capillary distribution network that will enable the distribution of Novo Nordisk’s products in the eleven markets across Asia Pacific.

Tanja Schaffer, Vice President, Global Pharmaceutical Industry, DKSH, commented: “We are very pleased to partner with Novo Nordisk Pharmatech in Asia Pacific. Their pharmaceutical grade quats are a perfect fit for our API portfolio. We look forward to providing the quats to our large customer base in the region and to building a prosperous relationship with Novo Nordisk Pharmatech.”

Steve Profit, Global Sales & Marketing Director at Novo Nordisk Pharmatech A/S, added: “For Novo Nordisk Pharmatech, it is critical that we have a distribution partner that shares our business ethics and drive to offer the best services to our customers, so we are delighted to have DKSH as our new distribution partner. Novo Nordisk Pharmatech’s FeF® GMP quats products fit perfectly with DKSH’s wide range of excipients, enabling the customers to take advantage of these synergies. Together, we will be able to offer the best quality and local distribution in the market. This will allow our customers to grow in this progressing global market.”

Learn more: www.dksh.com/novonordiskpharmatech

About DKSH

DKSH is the leading Market Expansion Services provider with a focus on Asia. As the term “Market Expansion Services” suggests, DKSH helps other companies and brands to grow their business in new or existing markets. Publicly listed on the SIX Swiss Exchange since 2012, DKSH is a global company headquartered in Zurich. With 825 business locations in 37 markets – 800 of them in Asia – and 31,970 specialized staff, DKSH generated net sales of CHF 11.0 billion in 2017. DKSH was founded in 1865. With strong Swiss heritage, the company has a long tradition of doing business in and with Asia and is deeply rooted in communities and businesses across Asia Pacific. 

DKSH Business Unit Performance Materials is a leading specialty chemicals distributor and provider of Market Expansion Services for performance materials, covering Europe, North America and the whole of Asia. The Business Unit sources, develops, markets and distributes a wide range of specialty chemicals and ingredients for pharmaceutical, personal care, food & beverage as well as various industrial applications. In addition, it creates innovative and cutting-edge concepts and applications in 29 innovation centers located worldwide. With 100 business locations in 31 markets and around 1,010 specialized staff, Business Unit Performance Materials generated net sales of CHF 894.1 million in 2017.

Wednesday 16.01.2019

Novo Nordisk Pharmatech A/S has entered into an agreement with Signet Chemical Corporation Pvt. Ltd. for the distribution of their pharmaceutical range of quaternary ammonium compounds (FEF® Quats) to the healthcare industry in India, Bangladesh and Sri Lanka.

Mr. Harish Shah – managing director of Signet commented on this new collaboration: “We are pleased to be associated with Novo Nordisk Pharmatech which is the leading supplier of Quats to the pharmaceutical and biopharmaceutical markets. Novo Nordisk Pharmatech’s FeF® Quats complement our existing portfolio of excipients used especially for ophthalmic, nasal and topical dosage forms”.

Novo Nordisk Pharmatech A/S manufactures Quats (Benzalkonium Chloride, Cetrimide and Cetyl Trimethyl Ammonium Bromide (CTAB), including customised grade, in accordance with cGMP (ICH Q7) for active pharmaceutical ingredients which is the highest available quality standard. Their products comply with the latest pharmacopoeial standards and are extensively supported by CEPs, DMFs and a comprehensive package of regulatory and quality assurance documents.  Their manufacturing site (Koege, Denmark) is audited by the Danish Medicines Agency and US FDA.

“We are very happy to work with Signet as our distribution partner for pharmaceuticals. Novo Nordisk Pharmatech’s FeF® Quats products fit perfectly with Signet’s wide range of excipients enabling the customers to take advantage of these synergies. We wish to give the best service to our customers and the local pharma team of Signet are experts in working with customers to support their product development” says Steve Profit, sales & marketing director at Novo Nordisk Pharmatech A/S.

About Signet

Signet, is India’s leading pharmaceutical excipient distributor company offering a broad range of excipients under one crest. Founded in 1986, Signet Chemical Corporation Pvt. Ltd. is a pioneer in the excipients business in India. Since its inception, Signet has combined technical expertise with commercial support to provide its clients accurate information and exceptional product value. With 95 qualified and well-trained members, the Signet team has an excellent understanding of the intricacies of the market and has strong relationships with key partners to take the company forward. Signet has a turnover of approx. 174 million US dollars with around 100 employees serving India, Bangladesh, Nepal and Sri Lanka.

Tuesday 31.07.2018

Novo Nordisk Pharmatech and Brenntag Specialties, Inc. (BSI) have entered into a distribution agreement for Pharmaceutical Grade Quaternary Ammonium Compounds into the Pharmaceutical and OTC Markets in the United States & Puerto Rico.

“Our partnership with Novo Nordisk Pharmatech demonstrates our commitment to providing innovative solutions and differentiated value to our customers by strategically expanding our principal relationships and product lines.” said Steve Brauer, President of Brenntag Specialties, Inc. “The product line offering from Novo Nordisk Pharmatech furthers our reach into the pharmaceutical, OTC, and personal care markets”

Novo Nordisk Pharmatech manufactures its Pharmaceutical Grade Quaternary Ammonium Compounds in accordance with the highest cGMP standards in the market- the ICH Q7A Guide for Active Pharmaceutical Ingredients.

The new product offering includes:

  • Benzalkonium Chloride and Cetrimide solutions
  • Benzalkonium Chloride 95%
  • Crystalline Cetrimide and Cetyl Trimethyl Ammonium Bromide

An innovative synthesis process makes Novo Nordisk Pharmatech a leading supplier of crystalline quaternary ammonium compounds. They have excellent antimicrobial and surface-active properties rendering them suitable for a variety of applications. High levels of purity make them particularly suited for specialized pharmaceutical applications, such as polysaccharide vaccine production and precipitation of DNA (gene therapy) vaccines. Quaternary ammonium compounds act either as preservatives or active ingredients in many ophthalmic, nasal, oral and topical drugs and in a variety of surgical scrubs, medicated solutions, ointments and creams.

Novo Nordisk Pharmatech manufactures quaternary ammonium compounds using only high-purity tertiary amines with various alkyl chain lengths, normally ranging from C12 to C18. The properties of our quaternary ammonium compounds can vary according to the alkyl chain length, but they all offer common attributes including:

  • Proven record of efficacy against a broad spectrum of microorganisms
  • Effective through a wide pH range
  • Odourless and colourless in product formulation
  • Surface active / adhesive cationic agent
  • Very stable, proven under ICH Q1 Stability Protocols
  • Five-year shelf life
  • Drug Master Files available for reference

About Brenntag:

Brenntag, the global market leader in chemical distribution, covers all major markets with its extensive product and service portfolio. Headquartered in Mülheim an der Ruhr, Germany, the company operates a global network with more than 490 locations in 72 countries. In 2014, the company, which has a global workforce of more than 13,500, generated sales of EUR 10.0 billion (USD 13.3 billion). Brenntag connects chemical manufacturers and chemical users. The company supports its customers and suppliers with tailor-made distribution solutions for industrial and specialty chemicals. With over 10,000 products and a world-class supplier base, Brenntag offers one-stop-shop solutions to around 170,000 customers. This includes specific application technology, an extensive technical support and value-added services such as just-in-time delivery, product mixing, formulation, repackaging, inventory management and drum return handling. Long-standing experience and local excellence in the individual countries characterize the global market leader for chemical distribution.

Saturday 01.07.2017

Novo Nordisk Pharmatech A/S has entered into an agreement with Azelis for the distribution of pharmaceutical grade quaternary ammonium compounds (quats) to the pharmaceutical and medical device markets in Germany, Spain, Portugal, UK and Ireland.

Matthew Dickman, Market Segment Director Pharma Azelis explains: “Novo Nordisk Pharmatech is the industry leader in pharmaceutical grade quats and we are delighted they have chosen Azelis Pharma as their distribution partner for the development of these markets. Novo Nordisk Pharmatech’s quats complement an existing Azelis portfolio of pharma antimicrobials. Alongside established uses of quats, our Pharma experts see potential new applications in the growing wound care market. Our local teams, who work with customers to support both their current and NPD requirements, will be investigating these options in the coming period.”

Novo Nordisk Pharmatech manufactures its quats (Benzalkonium Chloride, Cetrimide and Cetyl Trimethyl Ammonium Bromide, including customised grades) to the highest (c)GMP standards. Their site (Koege/Denmark) is audited by the Danish Medicines Agency and US-FDA. Products comply with the latest major pharmacopoeia and are supported by CEPs, DMFs and a comprehensive package of regulatory and quality assurance documents.

“We are very happy to work with Azelis as our distribution partner for our cGMP Quats. Novo Nordisk Pharmatech’s FeF™Quats products fit perfectly with Azelis existing antimicrobial portfolio enabling the customers to take advantage of these synergies. We wish to give the best service to our customers and the local pharma teams of Azelis are experts in working with customers to support their current and product development requirements.” says Steve Profit, Sales & Marketing Director at Novo Nordisk Pharmatech A/S.

About Azelis

Azelis is the leading global speciality chemicals distributor providing a diverse range of innovative products and services. Dedicated teams serve customers in the following industries: Personal Care, Pharma, Food & Health, Animal Nutrition, Specialty Agri/Horti, Homecare & Industrial Cleaning, CASE (coatings, adhesives, sealants, elastomers) Chemicals, Lubricants & Metal Working Fluids and Rubber & Plastic Additives. Through sourcing and distribution channels in every major market around the world, Azelis with its corporate service centre in Antwerp, Belgium, offers chemical producers market penetration, in-depth local knowledge, value-added services and tailored multi-territory solutions. Azelis has a turnover of ca. €1.5 billion and employs around 1,500 knowledgeable people located in more than 45 facilities in over 35 countries across the EMEA, Asia Pacific and Americas regions.

Tuesday 30.05.2017